In a report released today, Serge Belanger from Needham maintained a Buy rating on Tricida (TCDA – Research Report), with a price target of $18.00. The company's shares closed last Wednesday at $7.17. According to TipRanks.com, Belanger is a 1-star analyst with an average return of -2.5% and a 35.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tricida with a $18.00 average price target, which is a 138.4% upside from current levels.
https://www.tipranks.com/news/blurbs/needham-sticks-to-its-buy-rating-for-tricida-tcda?utm_source=advfn.com&utm_medium=referral
Tricida (NASDAQ:TCDA)
Gráfico Histórico do Ativo
De Nov 2022 até Dez 2022 Click aqui para mais gráficos Tricida.
Tricida (NASDAQ:TCDA)
Gráfico Histórico do Ativo
De Dez 2021 até Dez 2022 Click aqui para mais gráficos Tricida.